Emergent BioSolutions (EBS) to Release Quarterly Earnings on Wednesday

Emergent BioSolutions (NYSE:EBS - Get Free Report) is scheduled to be announcing its earnings results after the market closes on Wednesday, May 1st. Analysts expect the company to announce earnings of ($3.65) per share for the quarter. Emergent BioSolutions has set its FY 2024 guidance at EPS and its Q1 2024 guidance at EPS.Persons interested in participating in the company's earnings conference call can do so using this link.

Emergent BioSolutions (NYSE:EBS - Get Free Report) last announced its quarterly earnings results on Wednesday, March 6th. The biopharmaceutical company reported ($0.77) earnings per share for the quarter, missing analysts' consensus estimates of ($0.33) by ($0.44). The firm had revenue of $276.60 million during the quarter, compared to analyst estimates of $247.63 million. Emergent BioSolutions had a negative net margin of 72.11% and a negative return on equity of 37.35%. During the same quarter in the prior year, the business earned ($0.31) earnings per share. On average, analysts expect Emergent BioSolutions to post $-14 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Emergent BioSolutions Trading Down 5.2 %

NYSE EBS traded down $0.12 during trading on Wednesday, reaching $2.17. 798,970 shares of the stock traded hands, compared to its average volume of 2,648,902. The stock's 50-day moving average price is $2.44 and its 200 day moving average price is $2.25. The company has a quick ratio of 0.54, a current ratio of 1.04 and a debt-to-equity ratio of 0.69. The firm has a market cap of $113.69 million, a price-to-earnings ratio of -0.15 and a beta of 1.20. Emergent BioSolutions has a fifty-two week low of $1.42 and a fifty-two week high of $10.88.

Analysts Set New Price Targets

Separately, Benchmark reaffirmed a "buy" rating and set a $5.00 price objective on shares of Emergent BioSolutions in a research note on Thursday, April 11th.

About Emergent BioSolutions

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.